ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundDiagnosing colorectal cancer in people below age 50 relies largely on the evaluation of symptoms despite recent recommendations to initiate screening at age 45. There is limited information on the positive predictive value (PPV) of symptoms as indicators of early-onset colorectal cancer.
methodsWe identified patients aged 42 to 49 years in three community-based health systems between 2012 and 2020 whose first recorded colonoscopy had a diagnostic indication, with symptoms present in the two years before the colonoscopy. We computed the PPV for colorectal cancer by each individual symptom, combinations of the three most common symptoms, and combinations of the three symptoms with the highest PPVs and computed 95% confidence intervals (CI). We also evaluated the PPV of recent symptoms stratified according to the timing of onset and estimated the PPV of symptoms when followed by positive or negative fecal testing.
resultsThe study included 28,198 patients. The PPV for specific symptoms, with or without other symptoms, was 2.4% (95% CI, 2.2%-2.7%) for blood loss and 4.5% (95% CI, 3.3%-5.9%) for positive fecal testing. Pairwise and three-way combinations of blood loss, diarrhea, and abdominal mass had PPV point estimates for colorectal cancer above 3%.
conclusionsOur study suggests that specific symptoms and combinations may identify patients with a ≥3% prevalence of colorectal cancer in those aged 42 to 49 and that fecal testing results may further identify patients with a higher probability of colorectal cancer. IMPACT: Future research is needed to develop high PPV strategies for identifying early-onset colorectal cancer without compromising sensitivity. See related In the Spotlight, p. 1233.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.